New Cancer targets

Targets for cancer therapy initially were very specific cell division targets. Nowadays, the targets have become very cancer specific, for e.g. targeting the BCR-ABL to target Chronic Myeloid Leukemia. However, a scientist in Australia has come up with a target that is very unlikely – tropomyosin.

Tropomyosin is a protein that along with actin is responsible for cellular structure. It is present in every cell and is an important requirement for the survival of the cell.

Dr Gunning has found differences in tropomyosin between the heart and cancer cells and has developed drug therapy in his lab that causes the cellular structure of cancer cell to specifically break down. Tropomyosin and actin together can specifically work as a sensor for apoptosis. Thus creating specific drugs that modulate the tropomyosin inside the cancer cell can affect the cancer specifically.

However, though the tropomyosin in the heart maybe different from that in the cancer cell, it remains to be seen how the therapy can spare normal cells and specifically kill cancer cells.

Watch the video and then Read more about the work in the link below.

{youtube}PW6VE073ynI{/youtube}

Similar Posts

  • |

    Default mode network

    When we are not focused on a task, mind-wandering or just idling, specific regions of the brain such as medial pre frontal cortex, angular gyrus, hippocampus become activated and are called the default mode network. This is thought to be important for self referential thought, memory and future planning. It has been mapped with resting…

  • Treatment of TB

    Tuberculosis (TB) is the no 1 infectious disease killer all over the world but there has not been much development in new therapeutics till recently. There are 2 ways to address TB. Vaccine and therapeutics. The current vaccine for TB has been BCG which is not very effective in adults is still useful in children…

  • |

    Open source protein models

    A company called Profluent (profluent.bio) has been developing protein models that can be used for designing new proteins (https://www.nature.com/articles/s41587-022-01618-2), modeling of new CRISPR-Cas sequences (https://www.nature.com/articles/s41586-025-09298-z) and developing LLM for protein generation (https://www.biorxiv.org/content/10.1101/2025.11.12.688125v1.article-info). What is amazing is that they have open sourced all their models and Profluent-E1 is available in GitHub to download and use. (https://github.com/Profluent-AI/E1)…

  • Deuterium based drugs

    The news story today is about Concert Pharmaceuticals partnering with Celgene to develop Concert’s deuterated compounds. Concert and Auspex are two pharmaceutical companies pursuing the deuterated compound as a unique drugs but the science is a bit of a mystery. Hydrogen and its isotope Deuterium exists in nature and thus any compound will exist in…

  • Cardiovascular disease

    Staccato comments on cardiovascular disease Heart attack – Most common reason is blockage but not every time. Angina is progressive blockage that is causing heart attack. EKG often times cannot show a heart attack. It shows 60-70% of time but not 100%. You don’t wait for the enzymes to go up in an emergency. Many…